Know Cancer

forgot password

A Phase 2 Randomized, Double-Blind, Multicenter Trial of Amplimexon® Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy Naïve Pancreatic Adenocarcinoma (Stage IV)

Phase 2
18 Years
Not Enrolling
Pancreatic Neoplasms

Thank you

Trial Information

A Phase 2 Randomized, Double-Blind, Multicenter Trial of Amplimexon® Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy Naïve Pancreatic Adenocarcinoma (Stage IV)

Inclusion Criteria:

1. Patients with histologically or cytologically confirmed, chemotherapy naive,
metastatic pancreatic adenocarcinoma (Stage IV). This does not include patients with
only locally advanced pancreatic cancer.

2. At least one unidimensional measurable metastatic lesion by contrast enhanced CT scan
(or MRI in patients ineligible for contrast enhanced CT) that are outside any prior
radiation port.

3. Age at least 18 years.

4. ECOG performance status 0 or 1.

5. No prior chemotherapy or radiation therapy.

6. Projected life expectancy at least 2 months.

7. If female, neither pregnant nor lactating.

8. If of child bearing potential must agree to, and be able to use adequate

9. Concomitant disease: No respiratory insufficiency requiring oxygen therapy; no angina
at rest; no myocardial infarction in previous 3 months; no life threatening
ventricular arrhythmias. No uncompensated CHF or NY Heart Association class 3 or 4
cardiac disease.

10. No other concurrent active malignancy.

11. No infection requiring parenteral antibiotic therapy at the start of protocol

12. Laboratory values within the following criteria:

Hgb greater than or equal to 9 gm/dL WBC greater than or equal 3,500/mm^3 ANC greater
than or equal 1,500/mm^3 Platelet count greater than or equal 100,000/mm^3 Creatinine
greater than or equal 2.0 Bilirubin less than or equal to 2.0 Hepatic enzymes (AST,
ALT) less than or equal 3 times upper limit of normal (ULN)

13. G6PD level greater than or equal lower limit of normal (LLN).

14. Able to render informed consent and follow protocol requirements.

Exclusion Criteria:

1. Patients with locally advanced, non-metastatic pancreas cancer (Stage III or below).

2. Age less than 18 years.

3. ECOG performance status 2 or greater.

4. Prior anticancer drug therapy for metastatic disease.

5. Ascites.

6. Prior abdominal or thoracic surgery < 4 weeks before the start of therapy.

7. Current or prior brain metastases. Brain MRI or CT required pre-registration only if
the patient has CNS symptoms indicating a need for evaluation.

8. Life expectancy projected less than 2 months.

9. Pregnancy or lactation.

10. Unable or unwilling to utilize medically acceptable contraception if of childbearing

11. Laboratory parameters outside of specified ranges, (see above).

12. Infection requiring parenteral antibiotics.

13. NY Heart Association stage 3 or 4 heart disease.

14. Unable to render informed consent.

15. Failure to meet any of the eligibility criteria as outlined above.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Overall Survival for the Intent to Treat Population

Outcome Description:

To compare the overall survival duration of the two treatment arms. Overall survival is measured from the time of randomization until reported death. Subjects were censored at last time known alive if lost to follow-up. Alive patients were censored at the last survival follow-up. Follow-up was monthly after off study treatment.

Outcome Time Frame:

up to 2 years

Safety Issue:


Principal Investigator

Evan Hersh, MD

Investigator Role:

Study Director

Investigator Affiliation:

AmpliMed Corporation


United States: Food and Drug Administration

Study ID:




Start Date:

April 2008

Completion Date:

June 2010

Related Keywords:

  • Pancreatic Neoplasms
  • pancreatic cancer
  • metastatic
  • chemotherapy naive
  • Neoplasms
  • Pancreatic Neoplasms



University of Michigan Ann Arbor, Michigan  48109-0624
Roswell Park Cancer Institute Buffalo, New York  14263
Fox Chase Cancer Center Philadelphia, Pennsylvania  19111
University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania  15213
Swedish Cancer Institute Seattle, Washington  98104
Hunterdon Regional Cancer Center Flemington, New Jersey  08822
University of Minnesota Minneapolis, Minnesota  55455
Arizona Clinical Research Center Tucson, Arizona  85712
Hematology Oncology Associates Morristown, New Jersey  07962
Lahey Clinic Burlington, Massachusetts  01805
University of New Mexico Albuquerque, New Mexico  87131
Northern Indiana Cancer Research Consortium South Bend, Indiana  
Hematology Oncology Associates Albuquerque, New Mexico  87106
Pottstown Memorial Medical Center Pottstown, Pennsylvania  19464
Peachtree Hematology And Oncology Consultants Atlanta, Georgia  30309
Birmingham Hematology and Oncology- US Oncology Birmingham, Alabama  35205
AZ Onc Associates D.B.A. Hematology Oncology- US Oncology Tucson, Arizona  85704
Rocky Mountain Cancer Center- US Oncology Denver, Colorado  80218
Ocala Oncology Center- US Oncology Ocala, Florida  34471
Cancer Centers of Florida- US Oncology Orlando, Florida  34761
Hematology Oncology Associates of Illinois- US Oncology Chicago, Illinois  60611
Cancer Care & Hematolog Specialists of Chicagoland- US Oncology Niles, Illinois  60714
Central Indiana Cancer Centers- US Oncology Indianapolis, Indiana  46227
Hope Center- US Oncology Terre Haute, Indiana  47802
University of Kentucky, Hematology/Oncology/BMT Clinical Research Lexington, Kentucky  40536-0093
Kansas City Cancer Center, LLC- US Oncology Kansas City, Missouri  64131
Comprehensive Cancer Centers of Nevada- US Oncology Las Vegas, Nevada  89169
University of New Mexico Cancer Center South Las Cruces, New Mexico  88011
New Mexico Cancer Care Associates- US Oncology Santa Fe, New Mexico  87505
Cancer Center of North Carolina- US Oncology Raleigh, North Carolina  27607
Medical Onc Assoc of Wyoming Valley, PC- US Oncology Kingston, Pennsylvania  18704
Associates in Hematology-Oncology P.C. US Oncology Upland, Pennsylvania  19013
Reading Hospital Regional Medical Center West Reading, Pennsylvania  19611
Sanford Clinic Sioux Falls, South Dakota  57104
Texas Oncology - Amarillo- US Oncology Amarillo, Texas  79106
Mamie Mcfaddin Ward Cancer Center, Texas Oncology- US Oncology Beaumont, Texas  77702
Texas Oncology P.A.- Bedford- US Oncology Bedford, Texas  76022
Texas Cancer Center at Medical City- US Oncology Dallas, Texas  75230
Texas Oncology P.A. - Dallas- US Oncology Dallas, Texas  75231
Methodist Charlton Cancer Center - Texas Oncology- US Oncology Dallas, Texas  75237
Texas Oncology - Odessa- US Oncology Odessa, Texas  79761
Scott and White Hospital and Clinics Temple, Texas  76508
Texas Oncology Cancer Care and Research Center- US Oncology Waco, Texas  76712
Texoma Cancer Center- US Oncology Wichita Falls, Texas  76310
Virginia Oncology Associates- US Oncology Norfolk, Virginia  23502
Onc & Hematology Assoc. of Southern VA, Inc D.B.A. - US Oncology Salem, Virginia  24153
Cancer Care Northwest- US Oncology Spokane, Washington  99202
Northwest Cancer Specialists- US Oncology Vancouver, Washington  98684